Navigation Links
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Date:11/16/2007

and Navelbine. Determining the safety of a single dose of ANX-530 was a secondary objective. In the first week, patients were dosed with either ANX-530 or Navelbine, and after a washout period, were dosed with the opposite drug during the second week of treatment. The FDA has indicated that this single clinical study, should it demonstrate pharmacokinetic equivalence between ANX-530 and Navelbine, would provide sufficient clinical data to support a Section 505(b)(2) NDA.

Pharmacokinetic equivalence was determined based on federal regulations and FDA guidance regarding bioequivalence studies. If the upper and lower bounds of the AUC ratio's and the Cmax ratio's 90% confidence interval ranged from 0.80 to 1.25, ANX-530 and Navelbine were considered to have equivalent pharmacokinetics. AUC is a measure of the total amount of the drug circulating in the body over time. Cmax is the maximum concentration of the drug measured in the blood at any given time. The results of a clinical study are actually estimates of what might be expected if the treatment were to be given to the entire population of interest. Confidence intervals indicate the precision of such an estimate. Pursuant to the study's protocol and statistical analysis plan, data from all 31 patients who received both study drugs were included in the analysis.

About ANX-530 (vinorelbine emulsion)

ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a generic chemotherapy agent. ANX-530 is designed to reduce the incidence and severity of vein irritation from intravenous-delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting microtubule formation and is a member of the vinca alkaloid class of antineoplastic agents. Vinorelbine is indicated as a single agent or in combination with cisplatin for treatment of advanced non-small cell lung cancer and has also shown activity in breast, ovarian, and other cancers.

About Section 505(b)(2)

Section 505(b)(2) of the
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
8. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ) today ... quarter of 2013 on Monday, February 3, 2014. A press ... close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... May 26 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) ... make a presentation regarding the business strategy of the Company at the Noble ... 1:00 p.m. EDT .  The conference will be held at the Hard Rock ... , , ...
... Inteplast Group,s Integrated Bagging Systems (IBS) Unit is ... packaging division from Uniflex Holdings, part of S. Walter Packaging ... and other medical packaging, and is a valued addition to ... name, sales and customer base into the Inteplast fold. , ...
Cached Medicine Technology:Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010 2Inteplast Acquires Medical Packaging Division 2
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... media and others interested in the chemical sciences are ... American Chemical Society (ACS) Webinars, focusing on how to ... programs. Scheduled for Thursday, Sept. 16, from 2 ... feature Josephine Yuen, Ph.D., NSF Program Director, speaking on ...
... for Personalized Medicine , Author: Shara Yurkiewicz, Summary: Ten ... the human genome, major changes have made their way ... Title: Personalized Medicine,s Ragged Edge, Author: Leonard M. Fleck, ... spin. But little attention has been given to some ...
... , THURSDAY, Sept. 9 (HealthDay News) -- A ... heads-up about the kinds of medical problems that may face ... to use a computational method to create a score based ... rate during the first three hours after birth. In a ...
... living in California, Laotian/Hmong-Americans have the lowest survival rates ... new study by researchers with the UC Davis School ... largest population-based examination of liver cancer rates among Asian-Americans, ... to detect and treat the disease earlier among Laotian/Hmong-Americans, ...
... Academy of Orthopaedic Surgeons (AAOS) recently approved and released ... periprosthetic joint infections of the hip and knee. Clinical ... ensure that patients receive high quality care. A ... organisms enter the wound during or at any point ...
... By Steven Reinberg HealthDay Reporter , ... their ability to lower cholesterol and prevent heart attacks ... rheumatoid arthritis, Israeli researchers report. "We ... were less likely to develop rheumatoid arthritis over a ...
Cached Medicine News:Health News:American Chemical Society Webinar focuses on NSF's small business funding programs 2Health News:The Hastings Center Report table of contents for September-October 2010 2Health News:The Hastings Center Report table of contents for September-October 2010 3Health News:New Tool Aims to Predict Problems in Preemies 2Health News:UC Davis study finds low liver cancer survival rates among Laotian/Hmong-Americans 2Health News:UC Davis study finds low liver cancer survival rates among Laotian/Hmong-Americans 3Health News:Joint replacement: Does this look infected to you? 2Health News:Joint replacement: Does this look infected to you? 3Health News:Statins May Guard Against Rheumatoid Arthritis 2Health News:Statins May Guard Against Rheumatoid Arthritis 3
... Handbook on Injectable Drugs is a ... it quick and easy to check ... you enter the selected drugs, clear ... so you can quickly take clinical ...
Providing patients and their advocates with a variety of information services and educational materials on clinical research....
... DrDrugs®: Drug Guide for ... over 760 Integrated Calculators ... comprehensive, up-to-date and practical ... in drug dosing calculation ...
Clinician's Pocket Drug Reference 2005 includes key elements of commonly used medications that are essential information for both the student and practicing physician....
Medicine Products: